Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
Source abstract
Abstract
ABSTRACT Biomimetics is an interdisciplinary field that involves studying the structures, functions, principles, and behaviors of biological systems to draw inspiration and apply this knowledge to technological innovation and engineering design, thereby addressing complex challenges. Biomimetic nanomedicine represents a specific application of biomimetics within the realm of nanomedicine, where biological components are mimicked to construct sophisticated nanodrug delivery systems. These biomimetic nanosystems exhibit multiple unique advantages, including targeted delivery to cells within the tumor microenvironment (TME), prolonged in vivo circulation time, enhanced antigen/adjuvant loading capacity, and high biocompatibility. These properties collectively enhance the efficacy of chemotherapy, radiotherapy, immunotherapy, and photodynamic therapy (PDT) by improving tumor‐specific targeting and reducing off‐target toxicity, thereby establishing biomimetic nanomedicines as a promising platform for reprogramming the TME. This review highlights the categorization, design principles, and manufacturing strategies of biomimetic nanodrugs, providing a systematic review of the interplay between the TME and biomimetic nanomedicines, and elucidating how their interaction potentiates tumor‐killing efficacy. Despite encouraging progress in biomimetic nanomedicines, challenges remain in their clinical translation, including biosafety concerns, scalable manufacturing processes, and optimal drug delivery efficiency. Advances in nanotechnology and precision engineering offer promising avenues for developing personalized biomimetic nanomedicines.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Sciences Anhui Medical University Hefei P. R. China
Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Anhui Medical University Hefei P. R. China
Department of Endocrinology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
Department of Thyroid and Breast Surgery The First Affiliated Hospital of Anhui Medical University Anhui Public Health Clinical Center Hefei Anhui P. R. China
References (100+)
Show source-provided references
1. 10.1186/s12943-021-01316-810.1186/s12943-021-01316-8 ↗
2. 10.1093/annonc/mdw16810.1093/annonc/mdw168 ↗
3. 10.3390/pharmaceutics1507182110.3390/pharmaceutics15071821 ↗
4. 10.1038/s41573-021-00155-y10.1038/s41573-021-00155-y ↗
5. 10.1038/s41571-024-00959-y10.1038/s41571-024-00959-y ↗
6. 10.1016/j.semcancer.2019.09.00410.1016/j.semcancer.2019.09.004 ↗
7. 10.1186/s12943-023-01714-010.1186/s12943-023-01714-0 ↗
8. 10.1146/annurev-physiol-021119-03462710.1146/annurev-physiol-021119-034627 ↗
9. 10.1007/s11427-017-9178-y10.1007/s11427-017-9178-y ↗
10. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
11. 10.1021/acs.accounts.9b0055910.1021/acs.accounts.9b00559 ↗
12. 10.1007/s11010-019-03545-410.1007/s11010-019-03545-4 ↗
13. 10.1016/j.jconrel.2011.11.02110.1016/j.jconrel.2011.11.021 ↗
14. 10.1002/adma.20240507510.1002/adma.202405075 ↗
15. 10.1016/j.cis.2017.08.00510.1016/j.cis.2017.08.005 ↗
16. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
17. 10.2217/nnm-2017-022510.2217/nnm-2017-0225 ↗
18. 10.1038/s41419-020-03221-210.1038/s41419-020-03221-2 ↗
19. 10.1038/s41568-021-00339-z10.1038/s41568-021-00339-z ↗
20. 10.1038/s41571-024-00859-110.1038/s41571-024-00859-1 ↗
21. 10.3389/fimmu.2024.148272810.3389/fimmu.2024.1482728 ↗
22. 10.1038/s41423-021-00741-510.1038/s41423-021-00741-5 ↗
23. 10.1016/j.coi.2019.04.00310.1016/j.coi.2019.04.003 ↗
24. 10.1016/j.ccell.2016.06.00310.1016/j.ccell.2016.06.003 ↗
25. 10.1126/scitranslmed.aav743110.1126/scitranslmed.aav7431 ↗
26. 10.1016/j.celrep.2024.11486810.1016/j.celrep.2024.114868 ↗
27. 10.1016/j.celrep.2015.11.05310.1016/j.celrep.2015.11.053 ↗
28. 10.1158/2159-8290.CD-19-007410.1158/2159-8290.CD-19-0074 ↗
29. 10.3390/cancers1321531810.3390/cancers13215318 ↗
30. 10.1038/s41392-021-00506-610.1038/s41392-021-00506-6 ↗
31. 10.3390/ijms2213699510.3390/ijms22136995 ↗
32. 10.1172/JCI12864410.1172/JCI128644 ↗
33. 10.1038/nature1203410.1038/nature12034 ↗
34. 10.1016/j.mam.2011.04.00510.1016/j.mam.2011.04.005 ↗
35. 10.1002/jcp.2642910.1002/jcp.26429 ↗
36. 10.1016/j.canlet.2024.21707610.1016/j.canlet.2024.217076 ↗
37. 10.1038/s41590-024-01896-910.1038/s41590-024-01896-9 ↗
38. 10.1038/s41416-020-01048-410.1038/s41416-020-01048-4 ↗
39. 10.1016/j.canlet.2022.21604310.1016/j.canlet.2022.216043 ↗
40. 10.3389/fimmu.2018.0001410.3389/fimmu.2018.00014 ↗
41. 10.3389/fimmu.2023.127123610.3389/fimmu.2023.1271236 ↗
42. 10.1038/s41577-021-00574-310.1038/s41577-021-00574-3 ↗
43. 10.1126/science.aaa620410.1126/science.aaa6204 ↗
44. 10.3389/fimmu.2020.0006010.3389/fimmu.2020.00060 ↗
45. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
46. 10.1002/JLB.MR0718-269R10.1002/JLB.MR0718-269R ↗
47. 10.3389/fimmu.2019.0120510.3389/fimmu.2019.01205 ↗
48. 10.3389/fimmu.2021.68338110.3389/fimmu.2021.683381 ↗
49. 10.1084/jem.2018145410.1084/jem.20181454 ↗
50. 10.1016/j.ccell.2018.03.01210.1016/j.ccell.2018.03.012 ↗
51. 10.1038/s41571-019-0175-710.1038/s41571-019-0175-7 ↗
52. 10.1016/j.canlet.2020.07.02210.1016/j.canlet.2020.07.022 ↗
53. 10.1186/s12943-020-01234-110.1186/s12943-020-01234-1 ↗
54. 10.3390/ijms2513734610.3390/ijms25137346 ↗
55. 10.1126/science.120294710.1126/science.1202947 ↗
56. 10.1016/j.trecan.2022.06.00810.1016/j.trecan.2022.06.008 ↗
57. 10.1002/cac2.1234510.1002/cac2.12345 ↗
58. 10.1038/s41423-023-01061-610.1038/s41423-023-01061-6 ↗
59. 10.4049/jimmunol.176.8.502310.4049/jimmunol.176.8.5023 ↗
60. 10.1186/s12943-019-0976-410.1186/s12943-019-0976-4 ↗
61. 10.3389/fimmu.2023.129525710.3389/fimmu.2023.1295257 ↗
62. 10.1186/s12943-022-01657-y10.1186/s12943-022-01657-y ↗
63. 10.1084/jem.2013191610.1084/jem.20131916 ↗
64. 10.4049/jimmunol.150095910.4049/jimmunol.1500959 ↗
65. 10.3390/ijms1912380510.3390/ijms19123805 ↗
66. 10.3390/cells1102031010.3390/cells11020310 ↗
67. 10.1038/s41392-021-00670-910.1038/s41392-021-00670-9 ↗
68. 10.1016/j.gendis.2022.10.00610.1016/j.gendis.2022.10.006 ↗
69. 10.3390/cancers1211324410.3390/cancers12113244 ↗
70. 10.1158/2326-6066.CIR-18-048110.1158/2326-6066.CIR-18-0481 ↗
71. 10.1080/15384101.2018.144430510.1080/15384101.2018.1444305 ↗
72. 10.3389/fonc.2018.0008110.3389/fonc.2018.00081 ↗
73. 10.1002/advs.20210099710.1002/advs.202100997 ↗
74. 10.1016/j.celrep.2015.08.07710.1016/j.celrep.2015.08.077 ↗
75. 10.1016/j.biochi.2021.01.00510.1016/j.biochi.2021.01.005 ↗
76. 10.1016/j.tips.2017.11.00710.1016/j.tips.2017.11.007 ↗
77. 10.1016/j.semcancer.2021.10.00210.1016/j.semcancer.2021.10.002 ↗
78. 10.18632/oncotarget.1240910.18632/oncotarget.12409 ↗
79. 10.1172/JCI15983910.1172/JCI159839 ↗
80. 10.1073/pnas.091443310710.1073/pnas.0914433107 ↗
81. Inhibition of HIF‐1α by PX‐478 Suppresses Tumor Growth of Esophageal Squamous Cell Cancer in Vitro and in Vivo
82. 10.2147/IJN.S44113510.2147/IJN.S441135 ↗
83. 10.3390/ijms2215810210.3390/ijms22158102 ↗
84. 10.1038/s41374-021-00699-y10.1038/s41374-021-00699-y ↗
85. 10.1158/1535-7163.MCT-18-122510.1158/1535-7163.MCT-18-1225 ↗
86. 10.1083/jcb.20190306610.1083/jcb.201903066 ↗
87. 10.1007/s00018-019-03351-710.1007/s00018-019-03351-7 ↗
88. 10.3389/fimmu.2018.0052710.3389/fimmu.2018.00527 ↗
89. 10.1016/j.it.2016.01.00410.1016/j.it.2016.01.004 ↗
90. 10.1007/s10456-014-9420-y10.1007/s10456-014-9420-y ↗
91. 10.3390/ijms2207376510.3390/ijms22073765 ↗
92. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
93. 10.3390/cells704002410.3390/cells7040024 ↗
94. 10.1146/annurev-immunol-032713-12014210.1146/annurev-immunol-032713-120142 ↗
95. 10.1007/s10555-020-09898-310.1007/s10555-020-09898-3 ↗
96. 10.1002/smll.20200648410.1002/smll.202006484 ↗
97. 10.1016/j.actbio.2020.05.02810.1016/j.actbio.2020.05.028 ↗
98. 10.1016/j.apsb.2023.03.00410.1016/j.apsb.2023.03.004 ↗
99. 10.1016/j.apsb.2019.01.01110.1016/j.apsb.2019.01.011 ↗
100. The Loading of human Erythrocytes with Small Molecules by Electroporation